Generics With Poor Bioavailability May Not Use 505(b)(2) "Paper" NDA
Executive Summary
Generic drug applicants may not use the paper NDA 505(b)(2) mechanism of approval for products that have a reduced rate of absorption compared to the innovator, FDA said in its "Guidance for Industry: Applications Covered by Section 505(b)(2)."
You may also be interested in...
Pfizer Norvasc Challenges: Mylan ANDA, Dr. Reddy’s 505(b)(2)
Pfizer's Norvasc patent suit against Mylan could still delay the launch of Mylan's generic amlodipine, despite the lack of a 30-month stay
Pfizer Norvasc Challenges: Mylan ANDA, Dr. Reddy’s 505(b)(2)
Pfizer's Norvasc patent suit against Mylan could still delay the launch of Mylan's generic amlodipine, despite the lack of a 30-month stay
Pfizer, Pharmacia Protest Inclusion Of Drug Innovator Data In "Paper NDAs"
Pfizer and Pharmacia are requesting that FDA revise a draft guidance so that "paper NDAs" approved under section 505(b)(2) of the Waxman/Hatch patent law would not be allowed to rely on non-published studies conducted by the product innovator.